Apogee Therapeutics (APGE) Short-term Investments (2023 - 2026)

Apogee Therapeutics (APGE) has 4 years of Short-term Investments data on file, last reported at $608.1 million in Q1 2026.

• Short-term Investments for Q1 2026 came in at $608.1 million, up 49.63% year-over-year; the trailing twelve-month figure through Mar 2026 was $608.1 million (up 49.63% YoY), and the FY2025 annual result was $598.6 million, up 58.01% from the prior year.
• Short-term Investments grew to $608.1 million in Q1 2026 per APGE's latest filing, from $598.6 million in the prior quarter.
• Over five years, Short-term Investments peaked at $608.1 million in Q1 2026 and troughed at $234.6 million in Q3 2023.
• A 4-year average of $401.0 million and a median of $381.2 million in 2025 frame the typical range for Short-term Investments.
• The sharpest annual moves came in 2024 and 2025: Short-term Investments surged 73.6% in 2024, then climbed 2.97% in 2025.
• A 4-year view of Short-term Investments shows it stood at $277.1 million in 2023, then soared by 36.7% to $378.9 million in 2024, then jumped by 58.01% to $598.6 million in 2025, then gained by 1.58% to $608.1 million in 2026.
• Business Quant data shows APGE's Short-term Investments at $608.1 million in Q1 2026, $598.6 million in Q4 2025, and $419.4 million in Q3 2025.